Mar 26, 2024 | Commentary
Politicians—Democrats and Republicans alike—regularly complain about high drug prices and the need for policy changes to make prescription medicines more affordable for patients (read: voters).
Jul 20, 2023 | News
MGA’s analysis of the competition as new adalimumab biosimilars enter market.
Jul 18, 2023 | Events
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?
Jun 26, 2023 | Commentary
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.